[go: up one dir, main page]

MX2023003973A - Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos. - Google Patents

Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos.

Info

Publication number
MX2023003973A
MX2023003973A MX2023003973A MX2023003973A MX2023003973A MX 2023003973 A MX2023003973 A MX 2023003973A MX 2023003973 A MX2023003973 A MX 2023003973A MX 2023003973 A MX2023003973 A MX 2023003973A MX 2023003973 A MX2023003973 A MX 2023003973A
Authority
MX
Mexico
Prior art keywords
degraders
stat
compositions
methods
same
Prior art date
Application number
MX2023003973A
Other languages
English (en)
Inventor
Bin Yang
Xiaozhang Zheng
Xiao Zhu
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of MX2023003973A publication Critical patent/MX2023003973A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona compuestos, composiciones de los mismos y métodos de uso de los mismos.
MX2023003973A 2020-10-07 2021-10-07 Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos. MX2023003973A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063088787P 2020-10-07 2020-10-07
US202063123337P 2020-12-09 2020-12-09
PCT/US2021/071762 WO2022077010A1 (en) 2020-10-07 2021-10-07 Stat degraders and uses thereof

Publications (1)

Publication Number Publication Date
MX2023003973A true MX2023003973A (es) 2023-04-24

Family

ID=81126142

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003973A MX2023003973A (es) 2020-10-07 2021-10-07 Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos.

Country Status (8)

Country Link
US (1) US20240293423A1 (es)
EP (1) EP4225303A4 (es)
JP (1) JP2023545730A (es)
AU (1) AU2021358130A1 (es)
CA (1) CA3194492A1 (es)
IL (1) IL301830A (es)
MX (1) MX2023003973A (es)
WO (1) WO2022077010A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120574283A (zh) 2019-04-05 2025-09-02 凯麦拉医疗公司 Stat降解剂和其用途
CN115677831A (zh) * 2021-07-22 2023-02-03 杭州和正医药有限公司 拟肽类stat降解药物、组合物及应用
WO2023192960A1 (en) * 2022-03-31 2023-10-05 Recludix Pharma, Inc. Stat modulators and uses thereof
WO2024064080A1 (en) * 2022-09-19 2024-03-28 Kymera Therapeutics, Inc. Stat6 degraders and uses thereof
WO2024233639A2 (en) * 2023-05-09 2024-11-14 Recludix Pharma, Inc. Stat degraders and uses thereof
WO2024238603A2 (en) * 2023-05-15 2024-11-21 Recludix Pharma, Inc. Stat degraders and uses thereof
WO2025049821A1 (en) * 2023-08-30 2025-03-06 Kymera Therapeutics, Inc. Stat6 degraders and uses thereof
WO2025217647A1 (en) * 2024-04-12 2025-10-16 Kymera Therapeutics, Inc. Stat6 degraders and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2373658A4 (en) * 2008-12-08 2012-05-23 Univ Michigan Office Of Technology Transfer STAT3 INHIBITORS AND THERAPEUTIC PROCEDURES WHERE THEREOF ARE USED
IL273432B (en) * 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
CN114269763A (zh) * 2019-03-26 2022-04-01 美国密歇根州立大学试剂中心 Stat3的小分子降解剂

Also Published As

Publication number Publication date
JP2023545730A (ja) 2023-10-31
AU2021358130A9 (en) 2024-06-27
WO2022077010A1 (en) 2022-04-14
EP4225303A1 (en) 2023-08-16
AU2021358130A1 (en) 2023-05-18
EP4225303A4 (en) 2025-02-19
US20240293423A1 (en) 2024-09-05
IL301830A (en) 2023-06-01
CA3194492A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
MX2022011437A (es) Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.
PH12023500015A1 (en) Irak degraders and uses thereof
PH12022551524A1 (en) Irak degraders and uses thereof
WO2021127283A3 (en) Irak degraders and uses thereof
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2023003973A (es) Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos.
PH12021500026A1 (en) Irak degraders and uses thereof
PH12023500023A1 (en) Cdk2 degraders and uses thereof
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
WO2020243415A3 (en) Tead inhibitors and uses thereof
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
WO2024039901A3 (en) Cdk2 degraders and uses thereof
WO2023049790A3 (en) Mdm2 degraders and uses thereof
PH12021553018A1 (en) New egfr inhibitors
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
ZA202309446B (en) Rapamycin analogs and uses thereof
EP4438117A3 (en) Tyk2 inhibitors and uses thereof
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2024005138A (es) Degradadores de cinasa-4 asociada al receptor de la interleucina-1 (irak-4) y sintesis de los mismos.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.